Treatment Patterns and Clinical Characteristics of Patients with Advanced Basal Cell Carcinoma in the Community Oncology Setting


Advanced basal cell carcinoma (aBCC) includes metastatic and locally advanced BCC that is inoperable (or with surgery contraindicated). We describe patient characteristics and treatment history for aBCC cases from community oncology. Nine cases of aBCC were found within the ACORN Data Warehouse, a community oncology database of >180,000 cancer patients. Data were summarized descriptively. Three illustrative case histories are presented. Patients were predominantly Caucasian (8/9), male (6/9), and over 60 (6/9). Four had metastatic disease; five had aBCC without metastasis. Five had a history of treatment for early stage BCC, including surgery (5/5), radiation (1/5), and none had chemotherapy. Those with history of early stage BCC had periods of apparent lack of follow-up and treatment. One had chemotherapy for aBCC (platinum based with radiation) and eight had radiation without chemotherapy. Patients had multiple comorbid serious medical conditions. Six were deceased, but only one was documented to have aBCC as cause of death. Advanced BCC is rare in community oncology settings. There appear to be gaps in the care and follow-up of patients with initial early stage BCC. More data and larger samples are needed from multi-specialty databases such as dermatology and head and neck surgery.

Share and Cite:

M. Walker, L. Schwartzberg, D. Chen, D. Ramanan, A. Houts and C. Reyes, "Treatment Patterns and Clinical Characteristics of Patients with Advanced Basal Cell Carcinoma in the Community Oncology Setting," Journal of Cancer Therapy, Vol. 4 No. 6A, 2013, pp. 24-31. doi: 10.4236/jct.2013.46A1004.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. I. Rubin, E. H. Chen and D. Ratner, “Basal-Cell Carcinoma,” New English Journal of Medicine, Vol. 353, No. 21, 2005, pp. 2262-2269. doi:10.1056/NEJMra044151
[2] American Cancer Society, “Cancer Facts and Figures 2011,” American Cancer Society, 2011.
[3] Bader RS, “Basal Cell Carcinoma. eMedicine,” 2012.
[4] J. S. Lo, S. N. Snow, G. T. Reizner, F. E. Mohs, P. O. Larson and G. J. Hruza, “Metastatic Basal Cell Carcinoma: Report of Twelve Cases with a Review of the Literature,” Journal of the American Academy of Dermatology, Vol. 24, No. 5, 1991, pp. 715-719. doi:10.1016/0190-9622(91)70108-E
[5] H. von Domarus and P. J. Stevens, “Metastatic Basal Cell Carcinoma. Report of Five Cases and Review of 170 Cases in the Literature,” Journal of the American Academy of Dermatology, Vol. 10, No. 6, 1984, pp. 1043-1060.
[6] R. L. Raszewski and B. Guyuron, “Long-Term Survival Following Nodal Metastases from Basal Cell Carcinoma,” Annals of Plastic Surgery, Vol. 24, No. 2, 1990, pp. 170-175. doi:10.1097/00000637-199002000-00012
[7] A. Wadhera, M. Fazio, G. Bricca and O. Stanton, “Metastatic Basal Cell Carcinoma: A Case Report and Literature Review. How Accurate Is Our Incidence Data?” Dermatology online Journal, Vol. 12, No. 5, 2006, p. 7
[8] H. W. Walling, S. W. Fosko, P. A. Geraminejad, D. C. Whitaker and C. J. Arpey, “Aggressive Basal Cell Carcinoma: Presentation, Pathogenesis, and Management,” Cancer Metastasis Reviews, Vol. 23, No. 3-4, 2004, pp. 389-402. doi:10.1023/B:CANC.0000031775.04618.30
[9] D. N. Ionescu, M. Arida and D. M. Jukic, “Metastatic Basal Cell Carcinoma: Four Case Reports, Review of Literature, and Immunohistochemical Evaluation,” Archives of Pathology & Laboratory Medicine, Vol. 130, No. 1, 2006, pp. 45-51.
[10] P. T. Ting, R. Kasper and J. P. Arlette, “Metastatic Basal Cell Carcinoma: Report of Two Cases and Literature Review,” Journal of Cutaneous Medicine and Surgery, Vol. 9, No. 1, 2005, pp. 10-15. doi:10.1007/s10227-005-0027-1
[11] B. A Carneiro, W. G Watkin, U. K. Mehta and B. E. Brockstein, “Metastatic Basal Cell Carcinoma: Complete Response to Chemotherapy and Associated Pure Red Cell Aplasia,” Cancer Investigation, Vol. 24, No. 4, 2006, pp. 396-400. doi:10.1080/07357900600705474
[12] J. D. Khandekar, “Complete Response of Metastatic Basal Cell Carcinoma to Cisplatin Chemotherapy: A Report on Two Patients,” Archives of Dermatology, Vol. 126, No. 12, 1990, p. 1660. doi:10.1001/archderm.1990.01670360128037
[13] J. A. Low and F. J. de Sauvage, “Clinical Experience with Hedgehog Pathway Inhibitors,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, Vol. 28, No. 36, 2010, pp. 5321-5326. doi:10.1200/JCO.2010.27.9943
[14] D. D. Von Hoff, P. M. LoRusso, C. M. Rudin, J. C. Reddy, R. L. Yauch, R. Tibes, G. J. Weiss, M. J. Borad, C. L Hann, J. R. Brahmer, H. M. Mackey, B. L. Lum, W. C. Darbonne, J. C. Marsters Jr., F. J. de Sauvage and J. A. Low, “Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma,” New English Journal of Medicine, Vol. 361, No. 12, 2009, pp. 1164-1172. doi:10.1056/NEJMoa0905360
[15] Genentech, “Drug Label for Vismodegib,” Genentech, 2012. information/erivedge/pdf/erivedge_prescribing.pdf?cid=erv_we_F001110_P000517&c=MBEVUA1012&utm_source=&utm_medium=cpc&utm_term=advanced%20basal%20cell%20carcinoma&utm_campaign=2012%20Erivedge%20Condition%20(Jan12)&gclid =CP2Si rM164CFQ1U7AodiEo9bg
[16] National Cancer Institute, “Basal Cell Carcinoma of the Skin,” 2008. topics/pdq/treatment/skin/Health Professional/page5
[17] R. Malhotra, S. C. Huilgol, N. T. Huynh and D. Selva, “The Australian Mohs Database, Part II: Periocular Basal Cell Carcinoma Outcome at 5-Year Follow-Up,” Ophthalmology, Vol. 111, No. 4, 2004, pp. 631-636. doi:10.1016/j.ophtha.2003.11.004
[18] R. M. Thomas and R. A., “Amonette Mohs Micrographic Surgery,” American Family Physician, Vol. 37, No. 3, 1988, pp. 135-142.
[19] M. Caccialanza, R. Piccinno, S. Percivalle and M. Rozza, “Radiotherapy of Carcinomas of the Skin Overlying the Cartilage of the Nose: Our Experience in 671 Lesions,” Journal of the European Academy of Dermatology and Venereology, Vol. 23, No. 9, 2009, pp. 1044-1049. doi:10.1111/j.1468-3083.2009.03247.x
[20] R. D. Lovett, C. A. Perez, S. J. Shapiro and D. M. Garcia, “External Irradiation of Epithelial Skin Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 19, No. 2, 1990, pp. 235-242. doi:10.1016/0360-3016(90)90529-S
[21] K. Moeholt, P. Pfeiffer, H. Aagaard and O. Hansen, “Local Recurrence of Basal Cell Carcinoma and Cisplatinum Containing Chemotherapy,” Acta Oncology, Vol. 36, No. 1, 1997, p. 87. doi:10.3109/02841869709100742
[22] A. D. Joshi, M. T. Forsyth, D. C. Fryefield, W. Lopez, D. M. Chen and D. D. Ramanan, “Demographic and Treatment Characteristics for Advanced Basal Cell Carcinoma (aBCC) in an Oncology Outpatient Setting,” ASCO Meeting Abstracts, Vol. 29, No. S15, 2011, Article ID: e19001.
[23] S. B. Edge and American Joint Committee on Cancer, “Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas,” In: S. B. Edge, D. R. Byrd, C. C. Compton, et al., Eds., AJCC Cancer Staging Manual, 7th Edition,. Springer, New York, 2010, pp. 301-314.
[24] M. E. Charlson, P. Pompei, K. L. Ales and C. R. MacKenzie, “A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation,” Journal of Chronic Diseases, Vol. 40, No. 5, 1987, pp. 373-383. doi:10.1016/0021-9681(87)90171-8

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.